肝门部胆管癌根治术区域淋巴结清扫范围探讨_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 汤朝晖 , 魏妙艳 , 唐陈伟 , 全志伟

上海交通大学医学院附属新华医院普外科（上海 200092）;

Corresponding author：

汤朝晖, Email: tangzhaohui@yahoo.com

Keywords：

DOI：

10.7507/1007-9424.201806056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 汤朝晖, 魏妙艳, 唐陈伟, 全志伟. 肝门部胆管癌根治术区域淋巴结清扫范围探讨. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(7): 775-778. doi: 10.7507/1007-9424.201806056 Copy

1.	Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 1996, 224(4): 463-475.
2.	Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 2012, 61(12): 1657-1669.
3.	Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014, 383(9935): 2168-2179.
4.	Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
5.	Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v28-v37.
6.	陈孝平, 项帅. 精准医学时代肝门部胆管癌的治疗. 中华消化外科杂志, 2018, 17(1): 3-8.
7.	中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013 版). 中华外科杂志, 2013, 51(10): 865-871.
8.	Guglielmi A, Ruzzenente A, Campagnaro T, et al. Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford), 2011, 13(4): 240-245.
9.	Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg, 2010, 251(4): 675-681.
10.	Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg, 2013, 258(1): 129-140.
11.	Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford), 2016, 18(6): 510-517.
12.	Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454.
13.	Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. Am J Surg, 2015, 210(4): 694-701.
14.	Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis. JAMA Surg, 2016, 151(10): 916-922.
15.	Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
16.	Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg, 2012, 147(1): 26-34.
17.	Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg, 2013, 257(4): 718-725.
18.	Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg, 1992, 79(7): 659-662.
19.	Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196.
20.	中国抗癌协会. 肝门部胆管癌规范化诊治专家共识(2015). 中华肝胆外科杂志, 2015, 21(8): 505-511.
21.	Greene FL, Page DL, FIeming ID, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York: Springer, 2002.
22.	Edge S, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York: Springer, 2010.
23.	国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗-外科专家共识. 临床肝胆病杂志, 2015, 31(1): 12-16.
24.	Mao K, Liu J, Sun J, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol, 2016, 31(2): 417-426.
25.	Hakeem AR, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054.
26.	Ruys AT, Kate FJ, Busch OR, et al. Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford), 2011, 13(12): 881-886.
27.	Unno M, Okumoto T, Katayose Y, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg, 2007, 14(5): 434-440.
28.	周倩静, 张桃, 吴文, 等. MRI及MRCP评估肝门部胆管癌可切除性应用价值研究. 中国实用外科杂志, 2011, 31(4): 316-318.
29.	杨晖, 关志伟, 富丽萍, 等. ¹⁸F-FDG PET/CT 在肝外胆管细胞癌术前诊断及分期中的价值. 中华核医学与分子影像杂志, 2017, 37(2): 65-69.
30.	王越琦, 王吉文, 张德祥, 等. 氟代脱氧葡萄糖 PET/CT 在肝门部胆管癌术前评估中的价值. 中华肝胆外科杂志, 2015, 21(3): 173-176.
31.	谷鑫金, 王保富, 刘荣. ¹⁸F-FDG PET/CT 在肝门部胆管癌术前评估中的应用. 中华医学杂志, 2012, 93(20): 1409-1412.

1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 1996, 224(4): 463-475.
2. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 2012, 61(12): 1657-1669.
3. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014, 383(9935): 2168-2179.
4. Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
5. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v28-v37.
6. 陈孝平, 项帅. 精准医学时代肝门部胆管癌的治疗. 中华消化外科杂志, 2018, 17(1): 3-8.
7. 中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013 版). 中华外科杂志, 2013, 51(10): 865-871.
8. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford), 2011, 13(4): 240-245.
9. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg, 2010, 251(4): 675-681.
10. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg, 2013, 258(1): 129-140.
11. Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford), 2016, 18(6): 510-517.
12. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454.
13. Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. Am J Surg, 2015, 210(4): 694-701.
14. Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis. JAMA Surg, 2016, 151(10): 916-922.
15. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
16. Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg, 2012, 147(1): 26-34.
17. Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg, 2013, 257(4): 718-725.
18. Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg, 1992, 79(7): 659-662.
19. Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196.
20. 中国抗癌协会. 肝门部胆管癌规范化诊治专家共识(2015). 中华肝胆外科杂志, 2015, 21(8): 505-511.
21. Greene FL, Page DL, FIeming ID, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York: Springer, 2002.
22. Edge S, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York: Springer, 2010.
23. 国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗-外科专家共识. 临床肝胆病杂志, 2015, 31(1): 12-16.
24. Mao K, Liu J, Sun J, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol, 2016, 31(2): 417-426.
25. Hakeem AR, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054.
26. Ruys AT, Kate FJ, Busch OR, et al. Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford), 2011, 13(12): 881-886.
27. Unno M, Okumoto T, Katayose Y, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg, 2007, 14(5): 434-440.
28. 周倩静, 张桃, 吴文, 等. MRI及MRCP评估肝门部胆管癌可切除性应用价值研究. 中国实用外科杂志, 2011, 31(4): 316-318.
29. 杨晖, 关志伟, 富丽萍, 等. ¹⁸F-FDG PET/CT 在肝外胆管细胞癌术前诊断及分期中的价值. 中华核医学与分子影像杂志, 2017, 37(2): 65-69.
30. 王越琦, 王吉文, 张德祥, 等. 氟代脱氧葡萄糖 PET/CT 在肝门部胆管癌术前评估中的价值. 中华肝胆外科杂志, 2015, 21(3): 173-176.
31. 谷鑫金, 王保富, 刘荣. ¹⁸F-FDG PET/CT 在肝门部胆管癌术前评估中的应用. 中华医学杂志, 2012, 93(20): 1409-1412.

Previous Article
肝门部胆管癌的治疗现状与展望
Next Article
肝门部胆管癌切除术中右肝动脉重建技巧

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝门部胆管癌根治术区域淋巴结清扫范围探讨

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content